

## Contents

**Abbreviations** *xix*

### **Part I Fundamentals of Cellular and Molecular Biology** 1

- 1 The Cell as the Basic Unit of Life** 3  
*Michael Wink*  
 References 8  
 Further Reading 8
- 2 Structure and Function of Cellular Macromolecules** 9  
*Michael Wink*
- 2.1 Structure and Function of Sugars 9  
 2.2 Structure of Membrane Lipids 13  
 2.3 Structure and Function of Proteins 17  
 2.4 Structure of Nucleotides and Nucleic Acids (DNA and RNA) 25  
 References 32  
 Further Reading 32
- 3 Structure and Functions of a Cell** 33  
*Michael Wink*
- 3.1 Structure of a Eukaryotic Cell 33  
 3.1.1 Structure and Function of the Cytoplasmic Membrane 33  
 3.1.1.1 Membrane Permeability 33  
 3.1.1.2 Transport Processes Across Biomembranes 34  
 3.1.1.3 Receptors and Signal Transduction at Biomembranes 37  
 3.1.2 Endomembrane System in a Eukaryotic Cell 40  
 3.1.3 Mitochondria and Chloroplasts 45  
 3.1.4 Cytoplasm 49  
 3.1.5 Cytoskeleton 51  
 3.1.6 Cell Walls 53  
 3.2 Structure of Bacteria 53  
 3.3 Structure of Viruses 55  
 3.4 Differentiation of Cells 56  
 3.5 Cell Death 60  
 References 61  
 Further Reading 61
- 4 Biosynthesis and Function of Macromolecules (DNA, RNA, and Proteins)** 63  
*Michael Wink*
- 4.1 Genomes, Chromosomes, and Replication 63  
 4.1.1 Genome Size 63

4.1.2	Composition and Function of Chromosomes	67
4.1.3	Mitosis and Meiosis	69
4.1.4	Replication	71
4.1.5	Mutations and Repair Mechanisms	72
4.2	Transcription: From Gene to Protein	77
4.3	Protein Biosynthesis (Translation)	81
	Further Reading	85
<b>5</b>	<b>Distributing Proteins in the Cell (Protein Sorting)</b>	<b>87</b>
	<i>Michael Wink</i>	
5.1	Import and Export of Proteins via the Nuclear Pore	87
5.2	Import of Proteins in Mitochondria, Chloroplasts, and Peroxisomes	88
5.3	Protein Transport into the Endoplasmic Reticulum	89
5.4	Vesicle Transport from the ER via the Golgi Apparatus to the Cytoplasmic Membrane	92
	References	94
	Further Reading	94
<b>6</b>	<b>Evolution and Diversity of Organisms</b>	<b>95</b>
	<i>Michael Wink</i>	
6.1	Prokaryotes	95
6.2	Eukaryotes	95
	References	101
	Further Reading	101
<b>Part II Standard Methods in Molecular Biotechnology 103</b>		
<b>7</b>	<b>Isolation and Purification of Proteins</b>	<b>105</b>
	<i>Thomas Wieland</i>	
7.1	Introduction	105
7.2	Producing a Protein Extract	106
7.3	Gel Electrophoretic Separation Methods	107
7.3.1	Principles of Electrophoresis	107
7.3.2	Native Gel Electrophoresis	107
7.3.3	Discontinuous Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)	107
7.3.4	Two-Dimensional (2D) Gel Electrophoresis and Isoelectric Focusing (IEF)	108
7.3.5	Detecting Proteins in Gels	108
7.4	Methods of Protein Precipitation	109
7.5	Column Chromatography Methods	109
7.5.1	General Principles of Separation	109
7.5.1.1	Size Exclusion Chromatography (Gel Filtration)	109
7.5.1.2	Hydrophobic Interaction Chromatography	111
7.5.1.3	Ion Exchange Chromatography	111
7.5.1.4	Hydroxyapatite Chromatography	112
7.5.2	Group-Specific Separation Techniques	112
7.5.2.1	Chromatography on Protein A or Protein G	112
7.5.2.2	Chromatography on Cibacron Blue (Blue Gel)	112
7.5.2.3	Chromatography on Lectins	112
7.5.2.4	Chromatography on Heparin	113
7.5.3	Purification of Recombinant Fusion Proteins	113
7.5.3.1	Chromatography on Chelating Agents	113
7.5.3.2	Chromatography on Glutathione Matrices	114

7.6	Examples	114
7.6.1	Example 1: Purification of Nucleoside Diphosphate Kinase from the Cytosol of Bovine Retina Rod Cells	114
7.6.2	Example 2: Purification of Recombinant His <sub>6</sub> -RGS16 After Expression in <i>E. coli</i>	114
	Further Reading	115
<b>8</b>	<b>Mass Spectrometry and Applications in Proteomics and Microbial Identification</b>	<b>117</b>
	<i>Andreas Schlosser and Wolf D. Lehmann</i>	
8.1	Principles of ESI and MALDI Mass Spectrometry	117
8.2	Instrumental Setup	118
8.3	Intact Protein Analysis	119
8.3.1	Protein Digestion	119
8.3.2	Peptide Fragmentation	119
8.3.3	Protein Identification with MS/MS Spectra	121
8.4	Protein and Proteome Quantification	121
8.4.1	Label-Free Quantification	121
8.4.2	Chemical Stable Isotope Labeling	121
8.4.3	Metabolic Stable Isotope Labeling	122
8.5	Protein–Protein Interaction Analysis	123
8.6	Analysis of Posttranslational Modifications	124
8.7	Microbial Identification and Resistance Detection	125
	References	126
<b>9</b>	<b>Isolation of DNA and RNA</b>	<b>129</b>
	<i>Hans Weiher</i>	
9.1	Introduction	129
9.2	DNA Isolation	129
9.3	RNA Isolation	131
9.3.1	Enrichment of mRNA	131
	Reference	131
<b>10</b>	<b>Chromatography and Electrophoresis of Nucleic Acids</b>	<b>133</b>
	<i>Hans Weiher</i>	
10.1	Introduction	133
10.2	Chromatographic Separation of Nucleic Acids	133
10.3	Electrophoresis	134
10.3.1	Agarose Gel Electrophoresis: Submarine Electrophoresis	134
10.3.2	Pulsed-Field Agarose Gel Electrophoresis	134
10.3.3	Polyacrylamide Gel Electrophoresis (PAGE)	135
	Further Reading	135
<b>11</b>	<b>Hybridization of Nucleic Acids</b>	<b>137</b>
	<i>Hans Weiher</i>	
11.1	Significance of Base Pairing	137
11.2	Experimental Hybridization: Kinetic and Thermodynamic Control	137
11.3	Analytical Techniques	138
11.3.1	Clone Detection, Southern Blotting, Northern Blotting, and Gene Diagnosis	138
11.3.2	Systematic Gene Diagnosis and Expression Screening Based on Gene Arrays	139
11.3.3	<i>In Situ</i> Hybridization	139
	References	140
	Further Reading	140

- 12 Use of Enzymes in the Modification of Nucleic Acids 141**  
*Ingrid Herr and Michael Wink*
- 12.1 Restriction Enzymes (Restriction Endonucleases) 141
  - 12.2 Ligases 142
  - 12.3 Methyltransferases 142
  - 12.4 DNA Polymerases 143
  - 12.5 RNA Polymerases and Reverse Transcriptase 144
  - 12.6 Nucleases 144
  - 12.7 T4 Polynucleotide Kinase 144
  - 12.8 Phosphatases 145
  - Further Reading 145
- 13 Polymerase Chain Reaction 147**  
*Richard Jäger and Hans Weiher*
- 13.1 Introduction 147
  - 13.2 PCR Methods 147
    - 13.2.1 Basic Principle 147
    - 13.2.2 Primer Design and Hot Start PCR 148
    - 13.2.3 Multiplex PCR 149
    - 13.2.4 RT-PCR 149
    - 13.2.5 Qualitative Analysis of the PCR Products 149
  - 13.3 PCR as a Quantitative Method 149
    - 13.3.1 PCR Phases and PCR Efficiency 149
    - 13.3.2 Quantitative Real-Time PCR 150
    - 13.3.3 Digital PCR 151
  - 13.4 Areas of Application 151
    - 13.4.1 Genome Analysis 151
    - 13.4.2 Cloning Techniques 152
    - 13.4.3 Gene Expression Studies 152
    - Further Reading 152
- 14 DNA Sequencing 153**  
*Richard Jäger and Hans Weiher*
- 14.1 Introduction 153
  - 14.2 The Sanger Method 153
  - 14.3 Pyrosequencing 154
  - 14.4 Second-Generation Sequencing: Illumina and Ion Torrent 155
    - 14.4.1 Overview 155
    - 14.4.2 The Illumina Sequencing System 155
    - 14.4.3 The Ion Torrent Sequencing System 156
  - 14.5 Third-Generation Sequencing Techniques 156
    - 14.5.1 Overview 156
    - 14.5.2 SMRT Sequencing 157
    - 14.5.3 Nanopore Sequencing 157
  - 14.6 The Impact of the DNA Sequencing Technology 158
    - References 158
    - Further Reading 158
    - Websites 158
- 15 Cloning Procedures 159**  
*Thomas Wieland and Susanne Lutz*
- 15.1 Introduction 159
  - 15.2 Construction of Recombinant Vectors 159
    - 15.2.1 Insert 159

15.2.2	Vector	161
15.2.3	Essential Components of Vectors	162
15.2.3.1	Bacterial Origin of Replication ( <i>ori</i> )	162
15.2.3.2	Antibiotic Resistance	162
15.2.3.3	Polylinkers	162
15.2.4	Cloning Using Recombination Systems	162
15.2.5	Further Components of Vectors for Prokaryotic Expression Systems	163
15.2.5.1	Promoter	163
15.2.5.2	Ribosome-Binding Site	163
15.2.5.3	Termination Sequence	164
15.2.5.4	Fusion Sequence	164
15.2.6	Further Components of Eukaryotic Expression Vectors	164
15.2.6.1	Eukaryotic Expression Vectors: Yeast	164
15.2.6.2	Eukaryotic Expression Vectors for Mammal Cells	165
15.2.6.3	Viral Expression Systems for Mammalian Cells	167
15.2.7	Nonviral Introduction of Heterologous DNA to Host Organisms (Transformation, Transfection)	168
15.2.7.1	Transformation of Prokaryotes	168
15.2.7.2	Transformation of Yeast Cells	169
15.2.7.3	Transfection of Mammal Cells	169
	Further Reading	170
<b>16</b>	<b>Expression of Recombinant Proteins</b>	<b>171</b>
	<i>Thomas Wieland</i>	
16.1	Introduction	171
16.2	Expression of Recombinant Proteins in Host Organisms	171
16.2.1	Expression in <i>E. coli</i>	172
16.2.2	Expression in Yeasts	175
16.2.3	Expression in Insect Cells	177
16.2.3.1	Expression Based on Recombinant Baculoviruses	177
16.2.3.2	Expression of Proteins in Stably Transfected Insect Cells	178
16.2.4	Expression of Proteins in Mammalian Cells	178
16.3	Expression in Cell-Free Systems	179
16.3.1	Expression of Proteins in Reticulocyte Lysates	180
16.3.2	Protein Expression Using <i>E. coli</i> Extracts	180
	Further Reading	180
<b>17</b>	<b>Patch Clamp Method</b>	<b>181</b>
	<i>Robert Kraft</i>	
17.1	Ion Channels	181
17.2	Technical Requirements of the Patch Clamp Method	181
17.3	Patch Clamp Configurations	182
17.4	Applications of the Patch Clamp Method	183
	Reference	185
	Further Reading	185
<b>18</b>	<b>Cell Cycle Analysis</b>	<b>187</b>
	<i>Stefan Wöfl</i>	
18.1	Introduction	187
18.2	Analyzing the Cell Cycle	187
18.3	Experimental Analysis of the Cell Cycle	189
18.3.1	Preparing Synchronized Cell Cultures of <i>S. cerevisiae</i>	189
18.3.1.1	Centrifugal Elutriation	190
18.3.1.2	Cell Cycle Arrest Using $\alpha$ -Factor	190
18.3.2	Identification of Cell Cycle Stages	191

18.3.2.1	Budding Index	191
18.3.2.2	Fluorescent Staining of the Nucleus	191
18.3.2.3	Detection of Cell Cycle Phases Using Fluorescent Proteins as Reporters	194
	Acknowledgments	195
	Further Reading	196
<b>19</b>	<b>Microscopic Techniques</b>	<b>197</b>
	<i>Stephan Diekmann</i>	
19.1	Introduction	197
19.2	Electron Microscopy	197
19.2.1	Cryo-electron Microscopy	199
19.2.2	Electron Tomography	199
19.3	Atomic or Scanning Force Microscopy	199
19.3.1	Force Spectroscopy	200
19.3.2	Advantages and Disadvantages	201
19.4	Light Microscopy	201
19.4.1	Deconvolution	202
19.4.2	Confocal Microscopy	202
19.4.3	Why Fluorescence?	203
19.4.4	Nanoscopy	203
19.5	Microscopy in the Living Cell	204
19.5.1	Analysis of Fluorescently Labeled Proteins <i>In Vivo</i>	205
19.5.2	Fluorescence Recovery After Photobleaching	206
19.5.3	Fluorescence Correlation Spectroscopy	206
19.5.4	Förster Resonance Energy Transfer and Fluorescence Lifetime Imaging Microscopy	207
19.5.5	Single-Molecule Fluorescence	207
	Further Reading	207
<b>20</b>	<b>Laser Applications</b>	<b>209</b>
	<i>Rainer Fink</i>	
20.1	Laser Development: A Historical Perspective	209
20.2	Types of Lasers and Setups	210
20.3	Properties of Laser Radiation	210
20.4	Applications	211
20.4.1	Laser Scanning Microscopy	211
20.4.2	Optical Tweezers	212
20.4.3	Laser Microdissection and Laser Therapy	212
20.4.4	Manufacturing of Products in Medical Technology and Biotechnology Products	213
	Further Reading	213
	<b>Part III Key Topics</b>	<b>215</b>
<b>21</b>	<b>Sequencing the Universe of Life</b>	<b>217</b>
	<i>Stefan Wiemann</i>	
21.1	What to Sequence?	217
21.1.1	Whole-Genome Sequencing	217
21.1.2	Exome Sequencing	220
21.1.3	(Gene) Panel Sequencing	220
21.1.4	RNA Sequencing	221
21.1.4.1	Tag- vs. Full-Length Sequencing	221
21.1.4.2	Sequencing of RNA Species and Modifications	221
21.1.4.3	Sequencing of Single Cells	222

21.1.4.4	<i>In Situ</i> Sequencing	222
21.1.5	(Whole-Genome) Bisulfite Sequencing of DNA	223
21.1.6	Sequencing to Characterize Chromatin Structure and Beyond	223
21.2	Sequencing Projects: Human	224
21.2.1	Initial Sequencing of the Human Genome	224
21.2.2	The 1000 Genomes Project: Assessing Natural Variation	224
21.2.3	Screening for Genetic Disease	225
21.2.4	Sequencing of Populations	226
21.2.5	TCGA and ICGC: Screening for Cancer Driver Mutations	226
21.3	Sequencing Other Species, Environments, ...	228
21.4	Sequencing in the Clinics: Personalizing Oncology	228
21.5	Sequencing in the Private Sector: Direct to Consumer Testing (DTC)	231
21.6	The Information Content of a Genome Sequence and Ethical Consequences	231
	References	232
<b>22</b>	<b>Cellular Systems Biology</b>	<b>239</b>
	<i>Melanie Boerries, Hauke Busch, and Rainer König</i>	
22.1	Introduction	239
22.2	Analysis of Cellular Networks by Top-Down Approaches	240
22.2.1	Motivation	240
22.2.2	Definitions and Construction of the Networks	240
22.2.3	Gene Set Enrichment Tests	241
22.2.4	Inferring Gene Regulators Employing Gene Regulatory Models	242
22.2.5	Network Descriptors	243
22.2.5.1	Scale-Free Networks	243
22.2.5.2	Centrality	243
22.2.5.3	The Clustering Coefficient	244
22.2.6	Detecting Essential Enzymes with a Machine Learning Approach	244
22.2.7	Elementary Flux Modes	244
22.3	Overview over Bottom-Up Modeling of Biochemical Networks	247
22.3.1	Motivation	247
22.3.2	Choosing Model Complexity and Model Building	248
22.3.3	Model Simulation	251
22.3.4	Model Calibration	252
22.3.5	Model Verification and Analysis	254
22.3.6	Examples	254
	Further Reading	258
	References	259
<b>23</b>	<b>Protein–Protein and Protein–DNA Interactions</b>	<b>261</b>
	<i>Peter Uetz and Ehmke Pohl</i>	
23.1	Protein–Protein Interactions	261
23.1.1	Classification and Specificity: Protein Domains	261
23.1.2	Protein Networks and Complexes	262
23.1.3	Structural Properties of Interacting Proteins	262
23.1.4	Which Forces Mediate Protein–Protein Interactions?	263
23.1.4.1	Thermodynamics	264
23.1.4.2	Energetics	264
23.1.5	Methods to Examine Protein–Protein Interactions	264
23.1.6	Theoretical Prediction of Protein–Protein Interactions	266
23.1.7	Regulation of Protein–Protein Interactions	266
23.1.8	Biotechnological and Medical Applications of Protein–Protein Interactions	268
23.2	Protein–DNA Interactions	269
23.2.1	Specific Protein–DNA Interaction	269

- 23.2.2 Thermodynamic Consideration 270
- 23.2.3 Methods to Study Protein–DNA Interactions 270
- 23.2.3.1 Structural Classification of Protein–DNA Complexes 270
- 23.2.4 Regulatory Networks and System Biology 270
- 23.2.5 Medical Importance of Protein–DNA Interactions 273
- 23.2.6 Biotechnological Applications 274
  - References 275
  - Further Reading 275
  
- 24 Bioinformatics 277**
  - Benedikt Brors*
  - 24.1 Introduction 277
  - 24.2 Data Sources 277
    - 24.2.1 Primary Databases: EMBL/GenBank/DDBJ, PIR, and Swiss-Prot 277
    - 24.2.2 Genome Databases: Ensembl and GoldenPath 278
    - 24.2.3 Motif Databases: BLOCKS, PROSITE, Pfam, ProDom, and SMART 278
    - 24.2.4 Molecular Structure Databases: PDB and SCOP 278
    - 24.2.5 Transcriptome Databases: SAGE, ArrayExpress, and GEO 279
    - 24.2.6 Reference Databases: PubMed, OMIM, and GeneCards 279
    - 24.2.7 Pathway Databases and Gene Ontology 279
  - 24.3 Sequence Analysis 280
    - 24.3.1 Kyte–Doolittle Plot, Helical Wheel Analysis, and Signal Sequence Analysis 280
    - 24.3.2 Pairwise Alignment 281
      - 24.3.2.1 Local/Global 281
      - 24.3.2.2 Optimal/Heuristic 282
    - 24.3.3 Alignment Statistics 282
    - 24.3.4 Multiple Alignment 282
  - 24.4 Evolutionary Bioinformatics 283
    - 24.4.1 Statistical Models of Evolution 283
    - 24.4.2 Relation to Score Matrices 284
    - 24.4.3 Phylogenetic Analysis 285
  - 24.5 Gene Prediction 285
    - 24.5.1 Neural Networks or HMMs Based on Hexanucleotide Composition 286
    - 24.5.2 Comparison with Expressed Sequence Tags or Other Genomes (*Fugu*, Mouse) 286
  - 24.6 Bioinformatics in Transcriptome and Proteome Analysis 287
    - 24.6.1 Preprocessing and Normalization 287
    - 24.6.2 Feature Selection 288
    - 24.6.3 Similarity Measures: Euclidean Distance, Correlation, Manhattan Distance, Mahalanobis Distance, and Entropy Measures 288
    - 24.6.4 Unsupervised Learning Procedures: Clustering, Principal Component Analysis, Multidimensional Scaling, and Correspondence Analysis 289
    - 24.6.5 Supervised Learning Procedures: Linear Discriminant Analysis, Decision Trees, Support Vector Machines, and ANNs 289
    - 24.6.6 Analysis of Overrepresentation of Functional Categories 290
  - 24.7 Analysis of Ultraparallel Sequencing Data 291
    - 24.7.1 Mapping of Ultraparallel Sequencing Data 291
    - 24.7.2 Genome (Re-)sequencing 292
    - 24.7.3 Transcriptome Sequencing 292
    - 24.7.4 ChIP-seq 293
    - 24.7.5 Epigenetic Analysis 293
    - 24.7.6 Single-Cell Analysis 294
    - 24.7.7 Bioethics of Human Sequencing Data 294
  - 24.8 Bioinformatic Software 294
    - Further Reading 295



<b>25</b>	<b>Drug Research</b>	297
	<i>Manfred Koegl, Ralf Tolle, Ulrich Deuschle, Claus Kremsner, and Michael Wink</i>	
25.1	Introduction	297
25.2	Active Compounds and Their Targets	297
25.2.1	Identification of Potential Targets in the Human Genome	298
25.2.2	Comparative Genome Analysis	298
25.2.3	Experimental Target Identification: <i>In Vitro</i> Methods	299
25.2.4	Experimental Identification of Targets: Model Organisms	300
25.2.5	Experimental Target Identification in Humans	300
25.2.6	Difference Between Target Candidates and Genuine Targets	301
25.2.7	Biologicals	301
25.2.8	DNA and RNA in New Therapeutic Approaches	302
25.2.9	Patent Protection for Targets	303
25.2.10	Compound Libraries as a Source of Drug Discovery	304
25.2.11	High-Throughput Screening	304
25.2.12	High-Quality Paramounts in Screening Assays	304
25.2.13	Virtual Ligand Screening	306
25.2.14	Activity of Drugs Described in Terms of Efficacy and Potency	307
25.2.15	Chemical Optimization of Lead Structures	307
25.3	Preclinical Pharmacology and Toxicology	308
25.4	Clinical Development	309
25.5	Clinical Testing	309
	Further Reading	310
<b>26</b>	<b>Drug Targeting and Prodrugs</b>	311
	<i>Gert Fricker</i>	
26.1	Drug Targeting	311
26.1.1	Passive Targeting by Exploiting Special Physiological Properties of the Target Tissue	311
26.1.2	Physical Targeting	312
26.1.3	Active Targeting	313
26.1.4	Cellular Carrier Systems	316
26.2	Prodrugs	316
26.2.1	Prodrugs to Improve Drug Solubility	316
26.2.2	Prodrugs to Increase Stability	317
26.3	Penetration of Drugs Through Biological Membranes	317
26.4	Prodrugs to Extend Duration of Effect	318
26.5	Prodrugs for the Targeted Release of a Drug	318
26.6	Prodrugs to Minimize Side Effects	320
	References	320
<b>27</b>	<b>Molecular Diagnostics in Medicine</b>	323
	<i>Stefan Wöfl and Reinhard Gessner</i>	
27.1	Introduction	323
27.2	Uses of Molecular Diagnostics	323
27.2.1	Introduction	323
27.2.2	Monogenic and Polygenic Diseases	323
27.2.3	Individual Variability in the Genome: Forensics	325
27.2.4	Individual Variability in the Genome: HLA Typing	325
27.2.5	Individual Variability in the Genome: Pharmacogenomics	325
27.2.6	Individual Variability in the Genome: Susceptibility to Infectious Diseases	326
27.2.7	Viral Diagnosis	326
27.2.8	Microbial Diagnosis and Resistance Diagnosis	327
27.3	Which Molecular Variations Should be Detected	327
27.3.1	Point Mutations	327

27.3.2	Insertions and Deletions	328
27.3.3	Nucleotide Repeats	328
27.3.4	Deletion or Duplication of Genes	328
27.3.5	Recombination Between Chromosomes	329
27.3.6	Epigenetic Changes	329
27.4	Molecular Diagnostic Methods	330
27.4.1	DNA/RNA Purification	331
27.4.2	Detection of Target Sequence and Known Sequence Variations	331
27.4.2.1	Nucleic Acid Tests	331
27.4.2.2	Quantitative PCR	332
27.4.2.3	Multiplexing of Nucleic Acid Detection: Nucleic Acid <b>Microarrays</b>	333
27.4.2.4	Production and Manufacture of Microarrays	334
27.4.2.5	Applications of Fragment Length Analysis	335
27.4.2.6	Minisequencing	336
27.4.2.7	Determination of Unknown Mutations	336
27.5	Outlook	337
	Further Reading	338
	Historic Article: “News & Views”	338
	Reviews	338
	Web Link	338
	Textbooks	338
<b>28</b>	<b>Recombinant Antibodies and Phage Display</b>	<b>339</b>
	<i>Gustavo Marçal Schmidt Garcia Moreira and Stefan Dübel</i>	
28.1	Introduction	339
28.2	Generation of Specific Recombinant Antibodies	340
28.2.1	Generation of Antibody Gene Libraries	341
28.2.2	Selection Systems for Recombinant Antibodies	342
28.2.2.1	Transgenic Mice with Human IgG Genes	342
28.2.2.2	<i>In Vitro</i> Selection Systems	342
28.3	Production and Purification of Recombinant Antibodies	348
28.4	Features and Applications of Recombinant Antibodies	349
28.4.1	Advantages of Recombinant Antibodies	349
28.4.2	Formats and Applications of Recombinant Antibodies	350
28.4.2.1	Camelid Antibodies and V <sub>H</sub> Domains	351
28.4.2.2	scFv and dsFv	351
28.4.2.3	scFv–Fc Fusions, Fc Engineering, and the Addition of Constant Domains	352
28.4.2.4	IgG, Fusion Proteins, and Derivatives for Therapy	352
28.4.2.5	Bispecific Antibodies	354
28.4.2.6	Chimeric Antigen Receptors (CARs)	355
28.4.3	The Future of Therapeutic Antibodies	355
28.4.4	Research and <i>In Vitro</i> Diagnostics	356
28.4.5	Intracellular and Cell-Penetrating Antibodies	356
28.5	Outlook	357
	Further Reading	357
	Textbooks	357
	References	358
<b>29</b>	<b>Genetically Modified Mice and Their Impact in Medical Research</b>	<b>361</b>
	<i>Rolf Sprengel and Mazahir T. Hasan</i>	
29.1	Overview	361
29.2	Transgenic Mice	362
29.2.1	Retroviral Infection	362
29.2.2	Pronuclear Injection	363

29.3	Homologous Recombination: Knockout (Knock-In) Mice	364
29.4	Endonuclease-Based Knockout Mice	366
29.5	Endonuclease-Based Knock-In Mice	367
29.6	Conditionally Regulated Gene Expression	367
29.7	Gene Transfer to Subpopulations of Cells	368
29.7.1	Electroporation of Mouse Embryos (Plasmid DNA)	368
29.7.2	Virus-Mediated Gene Transfer (Lentivirus, rAAVs)	369
29.7.3	Virus-Mediated Gene Deletion (Cre/lox)	370
29.7.4	Virus-Mediated Gene Knockdown (shRNA, Antagomirs)	370
29.8	Impact of Genetically Modified Mice in Biomedicine	370
29.8.1	Alzheimer's Disease	370
29.8.2	Amyotrophic Lateral Sclerosis (ALS)	370
29.8.3	Psychological and Cognitive Disorders	371
29.8.4	Autism Spectrum Disorder (ASD)	371
29.8.5	Chemogenetics, Optogenetics, and Magnetogenetics	372
29.9	Outlook	372
	Reference	373
	Further Reading	373
<b>30</b>	<b>Plant Biotechnology</b>	<b>375</b>
	<i>Helke Hillebrand and Rüdiger Hell</i>	
30.1	Introduction	375
30.1.1	Green Genetic Engineering: A New Method Toward Traditional Goals	375
30.1.2	Challenges in Plant Biotechnology	376
30.2	Gene Expression Control and Genome Editing	376
30.2.1	Gene Expression Control	377
30.2.2	Genome Editing	377
30.3	Production of Transgenic Plants	378
30.3.1	Transformation Systems	379
30.3.1.1	<i>Agrobacterium</i> as a Natural Transformation System	379
30.3.1.2	Biolistic Method: Gene Gun	381
30.3.1.3	Plastid Transformation	382
30.3.1.4	Viral Systems	382
30.4	Selection of Transformed Plant Cells	383
30.4.1	Requirements for an Optimal Selection Marker System	383
30.4.2	Negative Selection Marker Systems	384
30.4.3	Positive Selection Marker Systems	385
30.4.4	Selection Systems, Genetic Engineering Safety, and Marker-Free Plants	385
30.5	Regeneration of Transgenic Plants	387
30.5.1	Regeneration Procedures	387
30.5.2	Composition of Regeneration Media	387
30.6	Plant Analysis: Identification and Characterization of Genetically Engineered Plants	388
30.6.1	DNA and RNA Verification	388
30.6.2	Protein Analysis	389
30.6.3	Genetic and Molecular Maps	389
30.6.4	Stability of Transgenic Plants	390
	Further Reading	390
<b>31</b>	<b>Biocatalysis in the Chemical Industry</b>	<b>393</b>
	<i>Michael Breuer and Bernhard Hauer</i>	
31.1	Introduction	393
31.2	Bioconversion/Enzymatic Procedures	395
31.3	Development of an Enzyme for Industrial Biocatalysis	397
31.3.1	Identification of Novel Biocatalysts	397

- 31.3.2 Improvement of Biocatalysts 399
- 31.3.3 Production of Biocatalysts 399
- 31.3.4 Outlook 399
- 31.3.5 Case Study 1: Screening for New Nitrilases 400
- 31.3.6 Case Study 2: Use of Known Enzymes for New Reactions: Lipases for the Production of Optically Active Amines and Alcohols 400
- 31.3.7 Case Study 3: Enzyme Optimization with Rational and Evolutive Methods 401
- 31.4 Fermentative Procedures 402
- 31.4.1 Improvement of Fermentation Processes 402
- 31.4.2 Classical Strain Optimization 403
- 31.4.3 Metabolic Engineering 404
- 31.4.4 Case Study 4: Fermentative Production of *n*-Butanol 405
- 31.4.5 Case Study 5: Production of Glutamic Acid with *C. glutamicum* 406
- 31.4.5.1 Molecular Mechanism of Glutamate Overproduction 406
- 31.4.6 Case Study 6: Production of Lysine with *C. glutamicum* 407
- 31.4.6.1 Molecular Mechanism of Lysine Biosynthesis 407
- 31.4.6.2 Deregulation of the Key Enzyme Aspartate Kinase 408
- 31.4.7 Genomic Research and Functional Genomics 409
- 31.4.8 Case Study 7: Fermentative Penicillin Production 409
- 31.4.9 Case Study 8: Vitamin B<sub>2</sub> Production 409
- 31.4.9.1 Riboflavin Biosynthesis 410
- 31.4.9.2 Classical Strain Development 410
- References 410

#### Part IV Biotechnology in Industry 411

### 32 Industrial Application: Biotech Industry, Markets, and Opportunities 413

*Julia Schöler*

- 32.1 Historical Overview and Definitions of Concepts 413
- 32.2 Areas of Industrial Application of Molecular Biotechnology 414
- 32.2.1 Red Biotechnology 414
- 32.2.1.1 Biopharmaceutical Drug Development 414
- 32.2.1.2 Gene and Cell Therapy 416
- 32.2.1.3 Tissue Engineering/Regenerative Medicine 419
- 32.2.1.4 Pharmacogenomics and Personalized Medicine 421
- 32.2.1.5 Molecular Diagnostic Agents 421
- 32.2.1.6 Systems Biology 422
- 32.2.1.7 Synthetic Biology 422
- 32.2.2 Green Biotechnology 422
- 32.2.2.1 Transgenic Plants 422
- 32.2.2.2 Genomic Approaches in Green Biotechnology 423
- 32.2.2.3 Novel Food and Functional Food 423
- 32.2.2.4 Livestock Breeding 423
- 32.2.3 White Biotechnology 424
- 32.3 Status Quo of the Biotech Industry Worldwide 424
- 32.3.1 Global Overview 424
- 32.3.2 United States 424
- 32.3.3 Europe 424

### 33 Patents in the Molecular Biotechnology Industry: Legal and Ethical Issues 425

*David Resnik*

- 33.1 Patent Law 425
- 33.1.1 What is a Patent? 425

33.1.2	How Does One Obtain a Patent?	426
33.1.3	What is the Proper Subject Matter for a Patent?	426
33.1.4	Types of Patents in Pharmaceutical and Molecular Biotechnology	427
33.1.5	Patent Infringement	427
33.1.6	International Patent Law	428
33.2	Ethical and Policy Issues in Biotechnology Patents	428
33.2.1	No Patents on Nature	428
33.2.2	Threats to Human Dignity	429
33.2.3	Problems with Access to Technology	430
33.2.4	Benefit Sharing	432
33.3	Conclusions	433
	Acknowledgments	433
<b>34</b>	<b>Drug Approval in the European Union and United States</b>	<b>435</b>
	<i>Gary Walsh</i>	
34.1	Introduction	435
34.2	Regulation Within the European Union	435
34.2.1	The EU Regulatory Framework	435
34.2.2	The EMA and National Competent Authorities	436
34.2.3	New Drug Approval Routes	437
34.2.3.1	The Centralized Procedure	437
34.2.3.2	Decentralized Procedure and Mutual Recognition	438
34.3	Regulation in the United States	438
34.3.1	CDER and CBER	439
34.3.2	The Approvals Procedure	439
34.4	The Advent and Regulation of Biosimilars	440
34.5	International Regulatory Harmonization	441
	References	442
<b>35</b>	<b>Emergence of a Biotechnology Industry</b>	<b>445</b>
	<i>Claus Kremoser</i>	
	Reference	451
	Further Reading	451
<b>36</b>	<b>The 101 of Founding a Biotech Company</b>	<b>453</b>
	<i>Claus Kremoser and Michael Wink</i>	
36.1	First Steps Toward Your Own Company	453
36.2	Employees: Recruitment, Remuneration, and Participation	456
<b>37</b>	<b>Marketing</b>	<b>459</b>
	<i>Claus Kremoser and Michael Wink</i>	
37.1	Introduction	459
37.2	What Types of Deals Are Possible?	460
37.3	What Milestone or License Fees Are Effectively Paid in a Biotech/Pharma Cooperation?	460
37.4	PR and IR in Biotech Companies	461
	Further Reading	462
	Websites	462
	<b>Glossary</b>	<b>463</b>
	<b>Index</b>	<b>491</b>

